Eton Pharmaceuticals (NASDAQ:ETON) Upgraded to Strong-Buy at Zacks Research

Eton Pharmaceuticals (NASDAQ:ETON) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

A number of other equities analysts also recently weighed in on the company. Craig Hallum upped their target price on Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. B. Riley Financial boosted their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday. HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $37.00 to $52.00 and gave the company a “buy” rating in a research note on Friday. Finally, Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.33.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock opened at $22.32 on Thursday. Eton Pharmaceuticals has a 12 month low of $11.09 and a 12 month high of $23.00. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19. The stock has a market cap of $598.58 million, a PE ratio of -123.99 and a beta of 1.19. The business has a fifty day simple moving average of $16.72 and a 200-day simple moving average of $17.38.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.07). The business had revenue of $21.28 million for the quarter, compared to analyst estimates of $20.58 million. Eton Pharmaceuticals had a negative net margin of 5.75% and a negative return on equity of 2.66%. On average, sell-side analysts anticipate that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several institutional investors have recently made changes to their positions in ETON. Deutsche Bank AG raised its stake in shares of Eton Pharmaceuticals by 4.9% in the 4th quarter. Deutsche Bank AG now owns 18,249 shares of the company’s stock valued at $309,000 after acquiring an additional 850 shares in the last quarter. Intech Investment Management LLC boosted its position in Eton Pharmaceuticals by 11.1% during the fourth quarter. Intech Investment Management LLC now owns 12,421 shares of the company’s stock worth $210,000 after purchasing an additional 1,244 shares during the period. Man Group plc boosted its position in Eton Pharmaceuticals by 6.0% during the second quarter. Man Group plc now owns 23,754 shares of the company’s stock worth $338,000 after purchasing an additional 1,350 shares during the period. State of Alaska Department of Revenue acquired a new position in Eton Pharmaceuticals during the third quarter valued at approximately $30,000. Finally, Quarry LP acquired a new position in Eton Pharmaceuticals during the third quarter valued at approximately $37,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.